PPARD and diabetes mellitus: Incontrast, the understanding of PPAR delta (δ)biology still lags behind.The identification of small moleculeagonists for PPAR-δ has shed some light on thefunction of this ubiquitously expressed receptor in preclinical models andearly clinicalstudies [3].They have revealed the multiple benefits of PPAR-δactivation on lipid disorders, diabetes, andinflammation[3, 4].However, synthetic PPAR-δ agonists have yet to bemarketed for clinical use in humans, partly due to the burdenassociated with their clinicaldevelopment [3].